Laparoscopic Ileocecal Resection versus Infliximab for Terminal Ileitis in Crohn’s Disease: a Randomized, Controlled, Open-Label, Multicentre Trial Lancet Gastroenterol Hepatol 2017;2:785–92

2018 ◽  
Vol 12 (2) ◽  
pp. 111-113
Author(s):  
Y. Panis
Keyword(s):  
Crohn’S Disease ◽  
Crohn's Disease ◽  
Multicentre Trial ◽  
Ileocecal Resection ◽  
Open Label ◽  
Terminal Ileitis ◽  
Randomized Controlled ◽  
Laparoscopic Ileocecal Resection

Cost-Effectiveness of Laparoscopic Ileocecal Resection Versus Infliximab Treatment of Terminal Ileitis In Crohn's Disease: The LIR!C Trial

2017 ◽  
Vol 152 (5) ◽  
pp. S185
Author(s):  
Joline de Groof ◽  
Willem Bemelman ◽  
Emma Eshuis ◽  
Tjibbe Gardenbroek ◽  
Patrick Bossuyt ◽  
...  
Keyword(s):  
Crohn’S Disease ◽  
Cost Effectiveness ◽  
Crohn's Disease ◽  
Ileocecal Resection ◽  
Infliximab Treatment ◽  
Terminal Ileitis ◽  
Laparoscopic Ileocecal Resection

Laparoscopic ileocaecal resection versus infliximab for terminal ileitis in Crohn's disease: a randomised controlled, open-label, multicentre trial

2017 ◽  
Vol 2 (11) ◽  
pp. 785-792 ◽  
Author(s):  
Cyriel Y Ponsioen ◽  
E Joline de Groof ◽  
Emma J Eshuis ◽  
Tjibbe J Gardenbroek ◽  
Patrick M M Bossuyt ◽  
...  
Keyword(s):  
Crohn’S Disease ◽  
Crohn's Disease ◽  
Multicentre Trial ◽  
Open Label ◽  
Terminal Ileitis ◽  
Randomised Controlled

scholarly journals Bacterial Mucosa-associated Microbiome in Inflamed and Proximal Noninflamed Ileum of Patients With Crohn’s Disease

2020 ◽  
Vol 27 (1) ◽  
pp. 12-24
Author(s):  
Maya Olaisen ◽  
Arnar Flatberg ◽  
Atle van Beelen Granlund ◽  
Elin Synnøve Røyset ◽  
Tom Christian Martinsen ◽  
...  
Keyword(s):  
Crohn’S Disease ◽  
Crohn's Disease ◽  
Beta Diversity ◽  
Ileocecal Valve ◽  
Alpha Diversity ◽  
Normal Mucosa ◽  
Ileocecal Resection ◽  
Ileal Mucosa ◽  
Terminal Ileitis ◽  
Endoscopic Recurrence

Abstract Background Microbiota is most likely essential in the pathogenesis of Crohn’s disease (CD). Fecal diversion after ileocecal resection (ICR) protects against CD recurrence, whereas infusion of fecal content triggers inflammation. After ICR, the majority of patients experience endoscopic recurrence in the neoterminal ileum, and the ileal microbiome is of particular interest. We have assessed the mucosa-associated microbiome in the inflamed and noninflamed ileum in patients with CD. Methods Mucosa-associated microbiome was assessed by 16S rRNA sequencing of biopsies sampled 5 and 15 cm orally of the ileocecal valve or ileocolic anastomosis. Results Fifty-one CD patients and forty healthy controls (HCs) were included in the study. Twenty CD patients had terminal ileitis, with endoscopic inflammation at 5 cm, normal mucosa at 15 cm, and no history of upper CD involvement. Crohn’s disease patients (n = 51) had lower alpha diversity and separated clearly from HC on beta diversity plots. Twenty-three bacterial taxa were differentially represented in CD patients vs HC; among these, Tyzzerella 4 was profoundly overrepresented in CD. The microbiome in the inflamed and proximal noninflamed ileal mucosa did not differ according to alpha diversity or beta diversity. Additionally, no bacterial taxa were differentially represented. Conclusions The microbiome is similar in the inflamed and proximal noninflamed ileal mucosa within the same patients. Our results support the concept of CD-specific microbiota alterations and demonstrate that neither ileal sublocation nor endoscopic inflammation influence the mucosa-associated microbiome.

Single Access Laparoscopic Ileocecal Resection in Complicated Crohn’s Disease

2010 ◽  
Vol 17 (4) ◽  
pp. 359-360 ◽  
Author(s):  
Giuseppe S. Sica ◽  
Sara Di Carlo ◽  
Livia Biancone ◽  
Paolo Gentileschi ◽  
Franco Pallone ◽  
...  
Keyword(s):  
Crohn’S Disease ◽  
Crohn's Disease ◽  
Ileocecal Resection ◽  
Single Access ◽  
Laparoscopic Ileocecal Resection

Polymeric Diet Alone Versus Corticosteroids in the Treatment of Active Pediatric Crohn’s Disease: A Randomized Controlled Open-Label Trial

2006 ◽  
Vol 4 (6) ◽  
pp. 744-753 ◽  
Author(s):  
Osvaldo Borrelli ◽  
Letizia Cordischi ◽  
Manuela Cirulli ◽  
Massimiliano Paganelli ◽  
Valeria Labalestra ◽  
...  
Keyword(s):  
Crohn’S Disease ◽  
Crohn's Disease ◽  
Open Label ◽  
Randomized Controlled ◽  
Open Label Trial

scholarly journals P833 Bacterial mucosa-associated microbiome in inflamed and proximal non-inflamed ileum of patients with Crohn’s disease

2020 ◽  
Vol 14 (Supplement_1) ◽  
pp. S645-S646
Author(s):  
M Olaisen ◽  
A Flatberg ◽  
A van Beelen Granlund ◽  
E S Røyset ◽  
T C Martinsen ◽  
...  
Keyword(s):  
Crohn’S Disease ◽  
Crohn's Disease ◽  
Ileocecal Valve ◽  
Ileocecal Resection ◽  
Dissimilarity Index ◽  
Ileal Mucosa ◽  
Terminal Ileitis ◽  
Β Diversity ◽  
Gastrointestinal Pathology ◽  
Α Diversity

Abstract Background The microbiota most likely has an essential role in the pathogenesis of Crohn’s disease (CD). While faecal diversion after ileocecal resection (ICR) protects against CD recurrence, re-exposure triggers inflammation. After ICR, the majority of patients develop recurrence in the neoterminal ileum and the ileal microbiome is of particular interest. We have therefore assessed the mucosa-associated bacterial microbiome in the inflamed and non-inflamed ileum of patients with CD. Methods Patients with an established diagnosis of CD undergoing ileocolonoscopy and healthy controls (HC) referred for colonoscopy due to rectal bleeding or screening for disease, but without any detected gastrointestinal pathology were invited to participate. Exclusion criteria included use of antibiotic treatment for the past 2 months. Mucosal pinch biopsies were sampled 5 cm and 15 cm orally of the ileocecal valve or ileocolic anastomosis for comparisons within the same patients. The biopsies were analysed by 16S rRNA sequencing, α- and β-diversity was assessed by Shannon entropy and Bray-Curtis dissimilarity index respectively. Histologic inflammation was graded. Results Fifty-one CD patients, where of 32 with previous ICR, and 40 HC were included in the study. Of the 51 CD patients, 20 had terminal ileitis, with endoscopically inflamed mucosa at 5 cm and normal appearing mucosa at 15 cm and no history of upper GI disease involvement. Seven CD patients had ileal stenosis. CD patients (n = 51) had lower α-diversity and separated clearly from HC on β-diversity plots (Figure 1). Twenty-three bacterial taxa were differentially represented in CD patients and HC, among these Tyzzerella 4 was found to be profoundly overrepresented in CD (p = 4.1 × 10–68). When comparing the microbiome in the inflamed ileal mucosa with the proximal non-inflamed mucosa within CD patients (n = 20) neither α- or β-diversity differed (Figure 2). Furthermore, no bacterial taxa were differentially represented in the inflamed vs. proximally non-inflamed mucosa. CD patients operated with ICR had lower α-diversity (p = 0.021), but β-diversity did not differ from CD patients without ICR. CD patients with stenosis had lower abundances of Bacteroides, Sutterella and Akkermansia species. Conclusion 23 taxa were differentially expressed in CD compared with HC. The ileal mucosa-associated microbiome is similar assessed by both α- and β-diversity in the inflamed mucosa and the proximal non-inflamed mucosa within the same patients. Our results support the concept of CD specific microbiota alterations and demonstrate that neither ileal sub-location nor endoscopic inflammation itself influence the mucosa-associated microbiome.

scholarly journals Single-port versus multiport laparoscopic ileocecal resection for Crohn's disease

2013 ◽  
Vol 7 (10) ◽  
pp. e443-e448 ◽  
Author(s):  
Tjibbe J. Gardenbroek ◽  
Tessa Verlaan ◽  
Pieter J. Tanis ◽  
Cyriel Y. Ponsioen ◽  
Geert R.A.M. D'Haens ◽  
...  
Keyword(s):  
Crohn’S Disease ◽  
Crohn's Disease ◽  
Single Port ◽  
Ileocecal Resection ◽  
Laparoscopic Ileocecal Resection

scholarly journals Early Ileocecal Resection Is an Effective Therapy in Isolated Crohn’s Disease

2021 ◽  
Vol 10 (4) ◽  
pp. 731
Author(s):  
Matthias Kelm ◽  
Friedrich Anger ◽  
Robin Eichlinger ◽  
Markus Brand ◽  
Mia Kim ◽  
...  
Keyword(s):  
Crohn’S Disease ◽  
Crohn's Disease ◽  
Primary Treatment ◽  
Early Surgery ◽  
Ileocecal Resection ◽  
Disease Manifestation ◽  
Terminal Ileitis ◽  
Primary Surgery ◽  
Immunosuppressive Medication

Despite the increasing incidence and prevalence of Crohn’s Disease (CD), no curative options exist and treatment remains complex. While therapy has mainly focused on medical approaches in the past, growing evidence reveals that in cases of limited inflammation, surgery can suffice as an alternative primary treatment. We retrospectively assessed the disease course and outcomes of 103 patients with terminal Ileitis who underwent primary surgery (n = 29) or received primary medical treatment followed by surgery (n = 74). Primary endpoint was the need for immunosuppressive medication after surgical treatment (ileocecal resection, ICR) during a two-years follow-up. Rates for laparoscopic ICR were enhanced in case of early surgery, but no differences were seen for postoperative complications. In case of immunosuppressive medication, patients with ICR at an early state of disease needed significantly less anti-inflammatory medication during the two-year postoperative follow-up compared to patients who were primarily treated medically. Furthermore, in a subgroup analysis for patients with localized ileocecal disease manifestation, early surgery consistently resulted in a decreased amount of medical therapy postoperatively. In conclusion primary ICR is safe and effective in patients with limited CD, and the need for immunosuppressive medication during the postoperative follow-up is low compared to patients receiving surgery at a later stage of disease.

Sign in / Sign up

Export Citation Format

Share Document